Advanced Pain Control – An innovation in pain control for those suffering from secondary bone cancer

Project Information

APAC

Grant agreement ID: 866986

DOI

10.3030/866986

Project closed

EC signature date 9 June 2019

Start date 1 July 2019

End date 31 December 2019

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

SCANDINAVIAN CHEMOTECH AB
Sweden

Periodic Reporting for period 1 - APAC (Advanced Pain Control – An innovation in pain control for those suffering from secondary bone cancer)

Reporting period: 2019-07-01 to 2019-12-31

Summary of the context and overall objectives of the project

Approximately 25% of all cancer patients are affected by secondary bone cancer, where malignant cells have spread to the bone from other areas. Bone is the third most frequent site of metastasis; a major cause for morbidity, characterized by severe pain, impaired mobility, pathologic fractures, and spinal cord compression. Patients with bone metastasis are treated using systemic therapy and pain control with narcotic analgesics, radiation therapy, and surgery. However, 20–30 % of patients do not respond to conventional treatments and continue to endure great pain and suffering. From a pain perspective, spinal tumours are the worst. Hence there is an unmet need for a treatment that alleviates the unbearable pain experienced by these patients and enables them to lead a more comfortable lifestyle free from debilitating back pain.
The overall objective of this project was to develop and optimize a business plan that will guide the development and commercialization of ChemoTech’s Dynamic-ElectroEnhanced Pain Control™ (D-EEPC), a revolutionary treatment for patients with bone cancer that alleviates pain through tumour bulk reduction

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

ChemoTech performed the feasibility study, which then will guide the overall company business development strategy. It provided a valuable understanding of current trends and opportunities on the bone cancer market, targeted users, and competitive landscape. A work plan for carrying out clinical studies that will prove the concept of electrochemotherapy for the treatment of spine cancer was also developed as part of the project.
The feasibility study has confirmed a clear and large business opportunity within the global bone cancer treatment market and to commercialize our revolutionary medical device for pain reduction in secondary bone cancer.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

This feasibility study has further confirmed the innovative character of ChemoTech’s approach. Our Dynamic-ElectroEnhanced Pain Control™ (D-EEPC) medical device is based on the already marketed IQWave™ platform. It sends short, high voltage electric pulses that, in combination with cytostatic drugs, reduce tumour size and pressure on nerves that cause pain. This medical device will substantially reduce pain associated with secondary bone cancer.
We strive to validate our promising results further and validate the potential for a medical device that will improve treatment, quality of life, decrease healthcare costs and ease the financial burden posed on healthcare budgets. The problem of bone cancer is growing and ChemoTech is convinced its innovative approach will have a significant impact on the burden that bone cancer imposes in Europe and worldwide.

ChemoTech's logo